GB201901305D0 - Specific binding molecules - Google Patents

Specific binding molecules

Info

Publication number
GB201901305D0
GB201901305D0 GBGB1901305.1A GB201901305A GB201901305D0 GB 201901305 D0 GB201901305 D0 GB 201901305D0 GB 201901305 A GB201901305 A GB 201901305A GB 201901305 D0 GB201901305 D0 GB 201901305D0
Authority
GB
United Kingdom
Prior art keywords
specific binding
binding molecules
molecules
specific
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1901305.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GBGB1901305.1A priority Critical patent/GB201901305D0/en
Publication of GB201901305D0 publication Critical patent/GB201901305D0/en
Priority to CA3127144A priority patent/CA3127144A1/en
Priority to MX2021009275A priority patent/MX2021009275A/es
Priority to PCT/EP2020/052315 priority patent/WO2020157210A1/en
Priority to KR1020217027112A priority patent/KR20210121141A/ko
Priority to AU2020215776A priority patent/AU2020215776A1/en
Priority to BR112021014963-5A priority patent/BR112021014963A2/pt
Priority to JP2021544406A priority patent/JP7530904B2/ja
Priority to EP20703192.3A priority patent/EP3917959A1/en
Priority to US17/427,592 priority patent/US12590152B2/en
Priority to IL284926A priority patent/IL284926B2/en
Priority to CN202080012045.4A priority patent/CN113728005B/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB1901305.1A 2019-01-30 2019-01-30 Specific binding molecules Ceased GB201901305D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1901305.1A GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules
CN202080012045.4A CN113728005B (zh) 2019-01-30 2020-01-30 Cd3特异性结合分子
KR1020217027112A KR20210121141A (ko) 2019-01-30 2020-01-30 Cd3-특이적 결합 분자
MX2021009275A MX2021009275A (es) 2019-01-30 2020-01-30 Moleculas de union especificas.
PCT/EP2020/052315 WO2020157210A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules
CA3127144A CA3127144A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules
AU2020215776A AU2020215776A1 (en) 2019-01-30 2020-01-30 CD3-specific binding molecules
BR112021014963-5A BR112021014963A2 (pt) 2019-01-30 2020-01-30 Molécula de ligação específica que se liga a cd3, molécula de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método de preparação da molécula de ligação específica que se liga a cd3, e método de tratamento
JP2021544406A JP7530904B2 (ja) 2019-01-30 2020-01-30 特異的結合性分子
EP20703192.3A EP3917959A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules
US17/427,592 US12590152B2 (en) 2019-01-30 2020-01-30 CD3-specific binding molecules
IL284926A IL284926B2 (en) 2019-01-30 2020-01-30 CD3-specific binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1901305.1A GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules

Publications (1)

Publication Number Publication Date
GB201901305D0 true GB201901305D0 (en) 2019-03-20

Family

ID=65997940

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1901305.1A Ceased GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules

Country Status (12)

Country Link
US (1) US12590152B2 (https=)
EP (1) EP3917959A1 (https=)
JP (1) JP7530904B2 (https=)
KR (1) KR20210121141A (https=)
CN (1) CN113728005B (https=)
AU (1) AU2020215776A1 (https=)
BR (1) BR112021014963A2 (https=)
CA (1) CA3127144A1 (https=)
GB (1) GB201901305D0 (https=)
IL (1) IL284926B2 (https=)
MX (1) MX2021009275A (https=)
WO (1) WO2020157210A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
KR20240149435A (ko) 2022-02-20 2024-10-14 이뮤노코어 리미티드 Hiv 특이적 결합 분자
MX2025001960A (es) 2022-08-18 2025-05-02 Immunocore Ltd Moléculas de unión multidominio
US12134647B2 (en) 2023-01-06 2024-11-05 Immunocore Limited Binding molecules
US12195534B2 (en) 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
TW202519257A (zh) * 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36676A (en) 1862-10-14 Improvement in grain-cleaners
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5855530Y2 (ja) 1981-06-15 1983-12-20 松下電工株式会社 照明器具を有する天井
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
UA129760C2 (uk) * 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
US12103971B2 (en) * 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
CA3265218A1 (en) * 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
US12195534B2 (en) * 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
US12134647B2 (en) * 2023-01-06 2024-11-05 Immunocore Limited Binding molecules

Also Published As

Publication number Publication date
BR112021014963A2 (pt) 2021-09-28
EP3917959A1 (en) 2021-12-08
JP7530904B2 (ja) 2024-08-08
CA3127144A1 (en) 2020-08-06
WO2020157210A1 (en) 2020-08-06
IL284926A (en) 2021-09-30
KR20210121141A (ko) 2021-10-07
CN113728005B (zh) 2025-02-21
AU2020215776A1 (en) 2021-09-09
US20220119527A1 (en) 2022-04-21
CN113728005A (zh) 2021-11-30
MX2021009275A (es) 2021-08-16
US12590152B2 (en) 2026-03-31
IL284926B1 (en) 2025-11-01
JP2022523507A (ja) 2022-04-25
IL284926B2 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
IL273631A (en) Special hpv molecules bind
IL281901A (en) Multivalent binding compounds based on IgM and IgA-Fc
IL275510A (en) Specific antigen-binding molecules-ROR1
GB201901306D0 (en) Multi-domain binding molecules
GB201901305D0 (en) Specific binding molecules
GB201811408D0 (en) CD137 Binding Molecules
IL289867A (en) Immunostimulatory multisegmented binding compounds
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201612520D0 (en) Binding molecules
GB201915282D0 (en) Specific binding molecules
GB201811410D0 (en) OX40 Binding molecules
IL287555A (en) binding compounds
GB202006629D0 (en) Specific binding molecules
GB201702091D0 (en) Specific binding molecules
IL288561A (en) gal9-binding molecules with immunosuppressive activity
IL289266A (en) new molecules
SG11202109535SA (en) Cd3 binding molecules
IL269752B (en) fgfr3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201904328D0 (en) Specific binding molecules
EP3976199A4 (en) ACTIVATION OF ANTI-GAL9 ANTIBODY BINDING MOLECULES
ZA202200734B (en) Binding members

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)